Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial

The Lancet

Volumn 386, Issue 9997, 2015, Pages 974-981

  Le Page, Emmanuelle ^a   Veillard, David ^a   Laplaud, David A ^b   Hamonic, Stéphanie ^a   Wardi, Rasha ^c   Lebrun, Christine ^d   Zagnoli, Fabien ^e   Wiertlewski, Sandrine ^f   Deburghgraeve, Véronique ^a   Coustans, Marc ^g   Edan, Gilles ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b Centre National de la Recherche Scientifique   (France)

^c Saint Brieuc Hospital   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e Military Hospital   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g Regional Hospital of Quimper   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PLACEBO; GLUCOCORTICOID;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NURSE; PATIENT COMFORT; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; SINGLE BLIND PROCEDURE; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FRANCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; FRANCE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941349922     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61137-0     Document Type: Article

References (28)

1. E Leray, J Yaouanq, E Le Page et al. Evidence of a two stage disability progression in multiple sclerosis Brain 133 2010 1900 1913
2. H Miller, D Newell, A Ridley Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH) Lancet 2 1961 1120 1122
3. L Durelli, D Cocito, A Riccio et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations Neurology 36 1986 238 243
4. NM Milligan, R Newcombe, DA Compston A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects J Neurol Neurosurg Psychiatry 50 1987 511 516
5. N Kapoor, CA Keever, N Leong, EX Beck Effects of ex vivo treatment with methylprednisolone and vincristine on bone marrow lymphohematopoietic cells Prog Clin Biol Res 377 1992 49 56
6. RW Beck, PA Cleary, JC Backlund The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial Ophthalmology 101 1994 1771 1778
7. RW Beck, JD Trobe What we have learned from the Optic Neuritis Treatment Trial Ophthalmology 102 1995 1504 1508
8. RW Beck Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis Lancet 349 1997 1696
9. A Citterio, L La Mantia, G Ciucci et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis Cochrane Database Syst Rev 4 2000 CD001331.
10. F Sellebjerg, JL Frederiksen, PM Nielsen, J Olesen Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS Neurology 51 1998 529 534
11. F Sellebjerg, HS Nielsen, JL Frederiksen, J Olesen A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis Neurology 52 1999 1479 1484
12. JM Burton, PW O'Connor, M Hohol et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis Cochrane Database Syst Rev 12 2012 CD006921.
13. SM Alam, T Kyriakides, M Lawden, PK Newman Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose J Neurol Neurosurg Psychiatry 56 1993 1219 1220
14. D Barnes, RA Hughes, RW Morris et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis Lancet 349 1997 902 906
15. C Ramo-Tello, L Grau-Lopez, M Tintore et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS Mult Scler 20 2014 717 725
16. V Martinelli, A Pulizzi, P Annovazzi et al. A single blind, randomised MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses Neurology 73 2009 1842 1848
17. SA Morrow, CA Stoian, J Dmitrovic, SC Chan, LM Metz The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis Neurology 63 2004 1079 1080
18. FD Lublin, SC Reingold, JA Cohen et al. Defining the clinical course of multiple sclerosis: the 2013 revisions Neurology 83 2014 278 286
19. CH Polman, SC Reingold, G Edan et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
20. JF Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
21. International Conference on Harmonisation ICH harmonised tripartite guideline - guideline for good clinical practice: E6(R1) http://www.hadassah.org.il/media/1875250/e6-r1--guideline.pdf (accessed Jan 31, 2012).
22. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects http://www.wma.net/en/30publications/10policies/b3/ (accessed June 15, 2015).
23. CW Dunnett, M Gent Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables Biometrics 33 1977 593 602
24. CW Dunnett, M Gent An alternative to the use of two-sided tests in clinical trials Stat Med 15 1996 1729 1738
25. FD Lublin, M Baier, G Cutter Effect of relapses on development of residual deficit in multiple sclerosis Neurology 61 2003 1528 1532
26. B Brochet Conférence de consensus. Indications thérapeutiques lors des poussées de sclérose en plaques Rev Neurol (Paris) 157 2001 988 995
27. F Lublin Oral megadose corticosteroid therapy of acute exacerbations of multiple sclerosis (OMEGA), NCT00418145 https://clinicaltrials.gov/ct2/show/NCT00418145
28. G Groenewould, H Hundt, H Luus et al. Absolute bioavailability of new high dose methylprednisolone tablet formulation Int J Clin Pharmacol Ther 32 1994 652 654